The factors affecting early death in newly diagnosed APL patients

被引:23
作者
Ciftciler, Rafiye [1 ]
Haznedaroglu, Ibrahim Celalettin [1 ]
Aksu, Salih [1 ]
Ozcebe, Osman [1 ]
Sayinalp, Nilgun [1 ]
Malkan, Umit Yavuz [2 ]
Buyukasik, Yahya [1 ]
机构
[1] Hacettepe Univ, Dept Hematol, Fac Med, Ankara, Turkey
[2] Diskapi Educ & Res Hosp, Dept Hematol, Ankara, Turkey
关键词
Acute promyelocytic leukemia; All-trans retinoic acid; Disseminated intravascular coagulation; ACUTE PROMYELOCYTIC LEUKEMIA; TRANS-RETINOIC ACID; REMISSION INDUCTION; RISK; PETHEMA;
D O I
10.1515/med-2019-0074
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background and aim: In the past, acute promyelocytic leukemia (APL) was considered as one of the most rapidly lethal form of acute myeloid leukemia (AML). The objective of this study was to assess clinical parameters affecting early death (ED) in patients with APL. Materials and methods: Forty-three patients with APL who were diagnosed at Hacettepe University Hospital between the years of 2005 and 2018 were evaluated. Results: In univariate analyses, presentation with hemorrhage, DIC or infection at diagnosis, ECOG performance score, blast percentage on bone marrow, Sanz score, leukocyte, thrombocyte, fibrinogen and LDH levels were found to be statistically significantly different between patients with ER and patients without ED. In multivariate analysis, presentation with hemorrhage, DIC or infection at diagnosis, ECOG performance score, blast percentage on bone marrow, Sanz score, leukocyte, thrombocyte, fibrinogen, and LDH levels were found to be independent factors that are related with higher rate of ED in 30 days after treatment. Conclusion: Induction chemotherapy should be started as soon as possible after diagnosis of APL. Improving ED rates may become the greatest challenge for the future treatment of the diseases.
引用
收藏
页码:647 / 652
页数:6
相关论文
共 24 条
[1]   Prospective validation of the International Society of Thrombosis and Haemostasis scoring system for disseminated intravascular coagulation [J].
Bakhtiari, K ;
Meijers, JCM ;
de Jonge, E ;
Levi, M .
CRITICAL CARE MEDICINE, 2004, 32 (12) :2416-2421
[2]   Early haemorrhagic morbidity and mortality during remission induction with or without all-trans retinoic acid in acute promyelocytic leukaemia [J].
Di Bona, E ;
Avvisati, G ;
Castaman, G ;
Vegna, ML ;
De Sanctis, V ;
Rodeghiero, F ;
Mandelli, F .
BRITISH JOURNAL OF HAEMATOLOGY, 2000, 108 (04) :689-695
[3]   Analysis of CD23 antigen expression in B-chronic lymphocytic leukaemia and its correlation with clinical parameters [J].
Jurisic, Vladimir ;
Colovic, Natasa ;
Kraguljac, Nada ;
Atkinson, Henry Dushan ;
Colovic, Milica .
MEDICAL ONCOLOGY, 2008, 25 (03) :315-322
[4]   The Actual Role of LDH as Tumor Marker, Biochemical and Clinical Aspects [J].
Jurisic, Vladimir ;
Radenkovic, Sandra ;
Konjevic, Gordana .
ADVANCES IN CANCER BIOMARKERS: FROM BIOCHEMISTRY TO CLINIC FOR A CRITICAL REVISION, 2015, 867 :115-124
[5]  
Kwaan HC, 2014, SEMINARS THROMBOSIS
[6]   Continuing high early death rate in acute promyelocytic leukemia: a population-based report from the Swedish Adult Acute Leukemia Registry [J].
Lehmann, S. ;
Ravn, A. ;
Carlsson, L. ;
Antunovic, P. ;
Deneberg, S. ;
Mollgard, L. ;
Derolf, A. Rangert ;
Stockelberg, D. ;
Tidefelt, U. ;
Wahlin, A. ;
Wennstrom, L. ;
Hoglund, M. ;
Juliusson, G. .
LEUKEMIA, 2011, 25 (07) :1128-1134
[7]   High dose ara-C in the treatment of newly diagnosed acute promyelocytic leukemia: long-term results of the German AMLCG [J].
Lengfelder, E. ;
Haferlach, C. ;
Saussele, S. ;
Haferlach, T. ;
Schultheis, B. ;
Schnittger, S. ;
Ludwig, W-D ;
Staib, P. ;
Aul, C. ;
Grueneisen, A. ;
Kern, W. ;
Reichle, A. ;
Serve, H. ;
Berdel, W. E. ;
Braess, J. ;
Spiekermann, K. ;
Woermann, B. ;
Sauerland, M-C ;
Heinecke, A. ;
Hiddemann, W. ;
Hehlmann, R. ;
Buechner, T. .
LEUKEMIA, 2009, 23 (12) :2248-2258
[8]  
Lo-Coco F, 2008, SEMINARS ONCOLOGY
[9]  
Mantha S, 2017, BLOOD
[10]  
Norgaard JM, 2019, EUROPEAN J HAEMATOLO